Robeco Institutional Asset Management B.V. Purchases 16,953 Shares of AnaptysBio, Inc. $ANAB

Robeco Institutional Asset Management B.V. acquired a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) during the third quarter, according to its most recent 13F filing with the SEC. The fund acquired 16,953 shares of the biotechnology company’s stock, valued at approximately $852,000. Robeco Institutional Asset Management B.V. owned 0.06% of AnaptysBio as of its most recent filing with the SEC.

Several other institutional investors have also added to or reduced their stakes in the business. Tema ETFs LLC raised its position in shares of AnaptysBio by 0.6% in the second quarter. Tema ETFs LLC now owns 31,270 shares of the biotechnology company’s stock valued at $2,111,000 after purchasing an additional 201 shares during the period. Arizona State Retirement System raised its holdings in AnaptysBio by 13.5% during the 2nd quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock valued at $295,000 after acquiring an additional 518 shares during the period. Persistent Asset Partners Ltd bought a new stake in AnaptysBio during the 2nd quarter valued at $39,000. State of Alaska Department of Revenue purchased a new stake in shares of AnaptysBio during the third quarter worth $85,000. Finally, Group One Trading LLC purchased a new stake in shares of AnaptysBio during the second quarter worth $140,000.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $95.00 price target on shares of AnaptysBio in a research report on Tuesday, September 22nd. Scotiabank cut AnaptysBio to a “hold” rating and set a $70.00 price objective on the stock. in a report on Tuesday, August 25th. Cantor Fitzgerald restated an “overweight” rating on shares of AnaptysBio in a research note on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a report on Friday, August 7th. Finally, TD Cowen reduced their target price on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a report on Tuesday, August 25th. Thirteen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $77.79.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $48.77 on Tuesday. The firm has a fifty day moving average price of $52.70 and a two-hundred day moving average price of $56.21. AnaptysBio, Inc. has a one year low of $20.18 and a one year high of $72.36. The company has a market cap of $1.46 billion, a price-to-earnings ratio of 9.08 and a beta of 0.76.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Monday, September 21st. The biotechnology company reported $5.11 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $5.57. AnaptysBio had a net margin of 82.37% and a return on equity of 112.00%. The firm had revenue of $27.49 million for the quarter, compared to analysts’ expectations of $14.06 million. During the same quarter in the prior year, the firm posted ($1.30) earnings per share. Equities research analysts expect that AnaptysBio, Inc. will post -1.30 EPS for the current fiscal year.

Insider Buying and Selling

In other AnaptysBio news, Director Hollings Renton sold 5,000 shares of the company’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $49.87, for a total value of $249,350.00. Following the transaction, the director directly owned 10,995 shares in the company, valued at $548,320.65. This represents a 31.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 31.50% of the stock is currently owned by insiders.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for immune-mediated diseases. The company uses its proprietary antibody discovery and engineering platform to identify therapeutics designed to modulate immune-system pathways involved in inflammation and autoimmune disorders.

AnaptysBio’s pipeline has included rosnilimab, an investigational antibody designed to activate the PD-1 immune checkpoint pathway, and imsidolimab, an investigational antibody targeting the interleukin-36 receptor.